B. Riley Has Negative Forecast for Novavax Q4 Earnings

Novavax, Inc. (NASDAQ:NVAX) – B. Riley lowered their Q4 2025 earnings per share (EPS) estimates for Novavax in a research report issued on Monday, November 10th. B. Riley analyst M. Mamtani now anticipates that the biopharmaceutical company will post earnings of ($1.36) per share for the quarter, down from their previous forecast of ($0.83). B. Riley has a “Buy” rating and a $16.00 price objective on the stock. The consensus estimate for Novavax’s current full-year earnings is ($1.46) per share. B. Riley also issued estimates for Novavax’s FY2026 earnings at ($0.42) EPS.

A number of other brokerages have also recently issued reports on NVAX. TD Cowen cut their price objective on shares of Novavax from $8.00 to $7.00 and set a “hold” rating for the company in a research note on Tuesday, November 4th. Wall Street Zen lowered shares of Novavax from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. Bank of America reiterated an “underperform” rating and issued a $7.00 price objective (down previously from $9.00) on shares of Novavax in a report on Wednesday, August 20th. HC Wainwright increased their target price on Novavax from $10.00 to $11.00 and gave the company a “buy” rating in a report on Thursday, October 23rd. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of Novavax in a research report on Wednesday, October 8th. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and four have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $11.38.

Novavax Stock Down 3.2%

Shares of NASDAQ NVAX opened at $7.20 on Wednesday. The stock has a market capitalization of $1.17 billion, a P/E ratio of 3.16, a PEG ratio of 0.12 and a beta of 2.69. Novavax has a one year low of $5.01 and a one year high of $11.55. The firm’s 50 day simple moving average is $8.38 and its two-hundred day simple moving average is $7.58. The company has a debt-to-equity ratio of 5.93, a current ratio of 2.36 and a quick ratio of 2.34.

Novavax (NASDAQ:NVAX) last announced its quarterly earnings data on Thursday, November 6th. The biopharmaceutical company reported ($1.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.08) by ($0.17). The firm had revenue of $70.45 million for the quarter, compared to analysts’ expectations of $55.63 million. Novavax had a net margin of 39.20% and a negative return on equity of 142.33%. The business’s quarterly revenue was down 16.7% on a year-over-year basis. During the same period in the prior year, the business posted ($0.76) earnings per share. Novavax has set its FY 2025 guidance at EPS.

Hedge Funds Weigh In On Novavax

Large investors have recently modified their holdings of the stock. Shah Capital Management boosted its holdings in Novavax by 3.4% in the second quarter. Shah Capital Management now owns 11,511,780 shares of the biopharmaceutical company’s stock worth $72,524,000 after purchasing an additional 379,934 shares during the last quarter. Park West Asset Management LLC bought a new position in shares of Novavax during the 1st quarter valued at $16,210,000. Allianz Asset Management GmbH lifted its holdings in shares of Novavax by 162.6% during the 3rd quarter. Allianz Asset Management GmbH now owns 1,409,734 shares of the biopharmaceutical company’s stock valued at $12,222,000 after buying an additional 872,987 shares during the period. TSP Capital Management Group LLC boosted its stake in shares of Novavax by 3.5% in the 2nd quarter. TSP Capital Management Group LLC now owns 1,399,065 shares of the biopharmaceutical company’s stock worth $8,814,000 after buying an additional 46,900 shares during the last quarter. Finally, SG Americas Securities LLC grew its holdings in shares of Novavax by 1.8% in the third quarter. SG Americas Securities LLC now owns 918,683 shares of the biopharmaceutical company’s stock worth $7,965,000 after acquiring an additional 15,997 shares during the period. Hedge funds and other institutional investors own 53.04% of the company’s stock.

About Novavax

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.